Trial reportFrontiers in immunology2018
Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Anti-p200 Pemphigoid: A Systematic Review.Frontiers in immunology · 2019Pooled it
- Factors associated with prolonged hospital stay in patients with autoimmune bullous diseases treated at an in-patient dermatology service.Skin health and disease · 2026Article
- A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease.International journal of molecular sciences · 2026Article
- Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.Postepy dermatologii i alergologii · 2026Article
- Mucosal Involvement in Bullous Pemphigoid: Severity Indicator and Associated Clinical Features from a Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.Acta dermato-venereologica · 2024Article
- Ocular involvement in oral vesiculobullous diseases: A review on reported cases in the literature.The Saudi dental journal · 2024Review
- Bullous pemphigoid with prominent mucosal involvement in the setting of renal allograft rejection.JAAD case reports · 2024Article
- From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid.International journal of molecular sciences · 2023Review
- A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy.Biomedicines · 2023Review
- Mixed muco-cutaneous pemphigoid: Clinical and immunological features of 15 cases.Frontiers in immunology · 2023Article
- Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.Frontiers in medicine · 2021Review
- Correlation of dermal and blood eosinophilia with bullous pemphigoid disease severity.International journal of women's dermatology · 2020Article
- Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.JAAD case reports · 2020Article
- Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.JAMA dermatology · 2019Article
- Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid.JAMA dermatology · 2019Article
- Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes/Macrophages and Mast Cells From Patients With Bullous Pemphigoid.Frontiers in immunology · 2019Article
- The Diagnosis and Blistering Mechanisms of Mucous Membrane Pemphigoid.Frontiers in immunology · 2019Review
- Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.Frontiers in immunology · 2018Article
- Diagnosis of Autoimmune Blistering Diseases.Frontiers in medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is the most common autoimmune bullous disease and typically affects the elderly. Binding of specific autoantibodies to BP180/230 hemidesmosomal components induces an inflammatory response leading to skin blister formation. Unusual manifestations of BP include additional mucous membrane involvement, without pathophysiological knowledge associated to the formation of these lesions. We here performed a prospective study on series of consecutive BP patients with (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.